tradingkey.logo

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™

ReutersJul 11, 2025 10:06 AM

- Milestone Pharmaceuticals Inc MIST.O:

  • MILESTONE PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE COMPANY’S RESPONSE TO THE CRL FOR CARDAMYST™ (ETRIPAMIL) NASAL SPRAY

  • MILESTONE PHARMACEUTICALS INC - FDA ASSIGNS PDUFA ACTION DATE OF DECEMBER 13, 2025

  • MILESTONE PHARMACEUTICALS INC - EXTENDS $75 MILLION ROYALTY AGREEMENT WITH RTW UNTIL 2025

  • MILESTONE PHARMACEUTICALS INC - TRANSFERRED DUTIES OF MANUFACTURING TESTING FACILITY TO VENDORS WITH FDA INSPECTION HISTORY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI